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During latent infection of neurons with herpes simplex virus type 1, viral transcription is restricted to the
latency-associated transcripts (LATs). These RNAs contain open reading frames, but detection of a protein
encoded by the LATs has not been reported. We used immunocytochemical techniques to demonstrate that an
antiserum directed against a bacterially expressed fusion protein containing part of a LAT-encoded polypeptide
recognized an antigen present in primary neurons latently infected in vitro. This antigen (called LAA, for
latency-associated antigen) was not detected in mock-infected neurons, in productively infected Vero cells, or
in neurons latently infected with a mutant virus carrying a deletion in the LAT gene. By Western immunoblot
analysis, we demonstrated the presence of a protein with an apparent molecular mass of 80 kDa recognized by
the anti-LAA antiserum in latently infected neurons.
The ability to establish a latent infection is a property
shared by several groups of viruses, including the herpesvi-
ruses. A latent infection is operationally defined as an
infection during which viral antigens characteristic of a
productive infection are not expressed although the viral
genome is present in the infected cell. Under certain condi-
tions the virus reactivates from the latent state and gives rise
to a productive infection. Herpes simplex virus type 1
(HSV-1) establishes a latent infection in neurons in humans
and in animal models. Following productive infection in the
periphery, HSV-1 gains access to the nerve terminals and is
transported by retrograde axonal transport to the cell body
of sensory neurons in the ganglia, where a latent infection
can be established. Certain stimuli, such as UV irradiation or
damage to tissue at the site of inoculation, cause viral
reactivation followed by anterograde transport of virus from
the ganglion to the periphery. This leads to a secondary
productive infection at the site of original inoculation. Re-
currence can occur throughout the life of an infected indi-
vidual (reviewed in references 8, 13, 14, and 18).
The molecular mechanisms involved in the establishment,
maintenance, and reactivation of the latent virus are not
understood. The only detectable viral RNAs in neurons of
latently infected ganglia are transcribed from the region of
the genome encoding the immediate-early gene ICPO and
have a polarity opposite to that of ICPO mRNA (3, 4, 16, 19).
The most abundant of these latency-associated transcripts
(LATs) is 2 kb long, and its 3' end overlaps with the 3' end
of ICPO mRNA (Fig. 1). In addition to the major form of
LAT, smaller species (1.5 and 1.45 kb) have been detected
(16, 22). Most, if not all, of these molecules are not polya-
denylated and are found in the nuclei of latently infected
neurons (16, 22). It has been proposed that the three forms of
LAT are derived by differential splicing from a larger pre-
cursor (6). The LAT has also been detected in the in vitro
model of HSV-1 latency used for this study (6a), in which a
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latent infection is established in primary neuronal cultures
prepared from fetal rat dorsal root ganglia (24-26).
A function has not yet been attributed to the LAT. The
hypothesis that LAT could inhibit ICPO expression through
an antisense mechanism and thus prevent a productive
infection was rejected after the finding that mutant viruses
lacking the LAT are able to establish a latent infection in
animal models (1, 2, 7, 9, 10, 12, 17). The LAT gene from the
KOS strain of HSV-1 encodes two open reading frames
(ORFs) (21). The larger of these ORFs (ORF 2) potentially
encodes a 305-amino-acid polypeptide and is highly con-
served among HSV-1 strains (21, 23).
We obtained antibodies against the potential polypeptide
encoded by LAT ORF 2 by immunizing rabbits with a
bacterially produced fusion protein containing part of this
polypeptide. The vector system we used to express the LAT
ORF 2 in Escherichia coli consists of a plasmid encoding
approximately 37 kDa of the bacterial trpE ORF under the
control of the inducible trp operon promoter (15). A poly-
linker at the 3' end of the trpE ORF allows in-frame insertion
of a foreign ORF. Using this system, we produced a chimeric
protein containing the carboxy-terminal part of the LAT
ORF 2 fused to the trpE ORF. The plasmid pATH-LAT2
encoding this chimeric gene is shown in Fig. 1. The plasmid
pATH-ICPO (Fig. 1) allowed the production of a fusion
protein containing the carboxy-terminal part of the third
exon of the immediate-early protein ICPO. The chimeric
proteins present in bacterial extracts were gel purified and
injected into rabbits, from which antisera were obtained.
The anti-LAT2 antiserum was shown to contain antibodies
against the LAT ORF 2; a polypeptide synthesized by in
vitro transcription and translation from a plasmid containing
part of the LAT ORF 2 was immunoprecipitated with this
antiserum (data not shown).
Immunocytochemistry experiments showed that neurons
latently infected in vitro were stained by the anti-LAT2
antiserum (Fig. 2A) but not by the anti-ICPO antiserum (Fig.
2B). Essentially all the neurons present in a latently infected
culture were stained with the anti-LAT2 antiserum. The
anti-ICPO antiserum provided a control to exclude the pos-
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FIG. 1. Plasmids used in this study. (A) General structure of
HSV-1 genome. UL, Unique long region; US, unique short region;
TRL, long terminal repeat; IRL, long internal repeat; IRS, short
internal repeat; TRS, short terminal repeat. The LAT and the ICPO
mRNAs are transcribed in opposite directions from the long repeat
regions. (B) Enlargement of the region of overlap between LAT and
ICPO mRNA. Viral ORFs are represented as open boxes, with N
referring to the amino and C to the carboxy terminus of each ORF.
Numbering is from reference 21.
sibility that the signal given by the anti-LAT2 antiserum
resulted from antibodies directed against the TrpE part of
the fusion protein. To determine the specifity of the signal
yielded by the anti-LAT2 antiserum, we used this antiserum
to stain mock-infected neuronal cell cultures (Fig. 2C) and
productively infected Vero cells (Fig. 2F). Similar cultures
were stained with the anti-ICP0 antiserum (Fig. 2D and G).
Mock-infected neurons did not react with either antiserum
(Fig. 2C and D), whereas the productively infected Vero
cells were stained only by the anti-ICPO antiserum (Fig. 2F
and G). Mock-infected Vero cells did not react with either
antiserum (not shown). We repeated these experiments with
neurons latently infected with the mutant virus d11403 (20),
in which both copies of the LAT gene have the Sall-XhoI
fragment deleted (Fig. 1B). Neurons infected with d11403
were not stained by the anti-LAT2 antiserum (Fig. 2E). The
mutant virus established a latent infection in vitro, as dem-
onstrated by virus reactivation; 100% (12 of 12) of the
cultures latently infected with d11403 produced infectious
virus after nerve growth factor deprivation, a stimulus
previously shown to reactivate latent HSV-1 (24, 26).
Western immunoblot analysis of whole-cell extracts from
latently infected neurons demonstrated the presence of a
protein with an apparent molecular weight of 80 kDa recog-
nized by the anti-LAT2 antiserum (Fig. 3A, lane 2). Whole-
cell extracts from mock-infected neurons (Fig. 3A, lane 1),
productively infected, or mock-infected Vero cells (data not
shown) did not contain detectable levels of this protein. The
anti-LAT2 antiserum also reacted with a 45-kDa polypeptide
present in latently infected neurons. The intensity of the
signal at 45 kDa varied from extract to extract, from barely
detectable to an intensity similar to that of the 80-kDa signal.
The 45-kDa band may represent a degradation product of the
80-kDa protein. More work is needed to clarify this point.
The anti-ICP0 antiserum (Fig. 3A, lane 4) but not the
anti-LAT2 antiserum (data not shown) allowed detection of
ICP0 (110 kDa) in nuclear extracts from productively in-
fected HeLa cells. To further examine the specificity of the
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FIG. 2. Detection of the latency-associated antigen (LAA) by immunocytochemistry. Neuronal cultures and establishment of latent
infection in vitro with the KOS strain of HSV-1 were done as described before (24-26). Indirect immunocytochemistry was done by the
avidin-biotin-glucose oxidase complex method according to the manufacturer's instructions (Vectastain; Vector Laboratories). Nitro Blue
Tetrazolium was used for the substrate, producing a purple-blue color, and the cells were counterstained with eosin. Cultures were fixed with
4% paraformaldehyde in phosphate-buffered saline (PBS). Immunoglobulins were obtained from serum by ammonium sulfate precipitation,
dissolved in PBS (half the original volume of serum), and used at a 1:500 dilution. The antisera used are indicated to the left. (A and B)
Latently infected neurons (14 days postinfection); (C and D) mock-infected neurons; (E) neurons infected with the LAT- mutant d11403 (20)
(14 days postinfection); (F and G) infected Vero cells (12 h postinfection).
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FIG. 3. Western blot analysis. Cells from neuronal cultures were
washed with an isotonic buffer, concentrated by centrifugation, and
lysed in buffer C (5). Cell debris was removed by centrifugation prior
to electrophoresis. HeLa cell nuclear extracts were obtained by the
method of Dignam et al. (5). Whole-cell extracts from neuronal cell
cultures (70 jig) or nuclear extracts from HeLa cells (25 ,ug) were
electrophoresed on polyacrylamide gels (11) and transferred to
nylon-supported nitrocellulose filters (Hybond Extra-C; Amer-
sham). The filters were incubated with the antisera (dilution, 1:300)
as indicated at the top of the figure, washed, incubated with
251I-protein A (0.1 pCi/ml; specific activity, >70 ,uCi/,g; New
England Nuclear), washed, and exposed for autoradiography. Ex-
tracts were from: M (lane Al), mock-infected neuronal cell cultures;
L (lanes A2, B1, and B2), latently infected neuronal cultures (14
days postinfection); U (lane A3), uninfected HeLa cells; and I (lane
A4), productively infected HeLa cells. Molecular masses are indi-
cated to the left (in kilodaltons) and are from prestained proteins
(Rainbow Markers; Amersham) that migrate slightly differently than
unstained proteins; therefore, the indicated molecular masses are
approximate.
80-kDa band recognized by the anti-LAT2 antiserum in
latently infected neurons, we performed the following exper-
iment. Protein samples from latently infected neurons and
productively infected HeLa cells were divided equally,
electrophoresed, and transferred to nitrocellulose; the filters
were probed with either anti-LAT2 or anti-ICPO antiserum
(Fig. 3B). The anti-ICPO antiserum did not react with the
80-kDa protein in latently infected neurons (Fig. 3B, lane 2),
although it reacted with ICPO on the same filter (data not
shown). Lane 1 is the positive control to show that the
80-kDa band was indeed present in the extract used in this
experiment. This result indicates that the 80-kDa signal is
not due to antibodies directed against the bacterial part of
the fusion protein.
The data from immunocytochemistry and Western blot
analysis show that the anti-LAT2 antiserum recognizes an
antigen (80 kDa) present only in latently infected neurons.
Our interpretation of these results is that the LAT-encoded
ORF 2 is translated in latently infected neurons. We have
called this protein latency-associated antigen (LAA). We are
currently investigating the status of this antigen in latently
infected ganglia.
The transcription pattern of the region encoding the LAT
is complex. Because of lack of polyadenylation and nuclear
localization, the 2-kb, 1.5-kb, and 1.45-kb LAT species may
not function as LAA mRNA. A series of low-abundance
LAT-related transcripts that extend several kilobases down-
stream from the major LAT 3' end to a polyadenylation
signal located 8.5 kb from the LAT TATA box have been
identified in productively infected cell cultures (6, 18). RNA
hybridizing to probes extending 5 kb downstream of the 3'
end of the major LAT has also been detected in latently
infected ganglia by in situ hybridization (6, 18). These RNA
molecules have been shown to be polyadenylated in produc-
tively infected cells (6, 18) and are presumably polyadeny-
lated in neurons as well. The current thinking is that the 2-kb
LAT is a stable intron from a larger transcript. Alternative
splicing resulting in polyadenylated transcripts containing
ORF 2 has not been ruled out, and such transcripts may
function as LAA mRNAs.
From its size (305 codons), the LAT ORF 2 would be
expected to yield a protein of about 33 kDa. There are
several possible explanations for the observed size of the
LAA. First, the polypeptide has a high proline content (59
residues, or about 19% of the amino acids encoded by the
ORF, are prolines) that could result in aberrant electropho-
retic mobility. Second, the primary translation product could
be modified by phosphorylation, glycosylation, or other
processes. Third, larger ORFs could be generated by RNA
splicing. Since the difference between the observed and
calculated sizes of the LAA is very large (about 50 kDa), the
third possibility is the most likely.
The function of this protein remains to be determined.
Despite the fact that the LAA is present in neurons during
the latent phase of infection, the ability of LAT- mutants to
establish latent infections (1, 2, 7, 9, 10, 12, 17) suggests that
LAT gene products are not necessary for the establishment
or maintenance of the latent state. Some reports indicate that
LAT- viruses (including the d11403 mutant used in this
study) show delayed reactivation kinetics in explantation
assays (2, 12, 17) or reduced efficiency of in vivo reactivation
(7), whereas other LAT- mutants reactivate with the same
kinetics as the wild-type virus (1, 9). It would be informative
to determine whether the delayed-reactivation phenotype in
this set of mutants correlates with an inability to express the
LAA. Interestingly, the two LAT- mutants that did not
show delayed reactivation had very minor (1) or no (9)
alteration in ORF 2; even though RNA encoded by this ORF
was not detected in ganglia infected with these mutants, one
cannot formally exclude the possibility that the LAA was
indeed produced under these conditions. Nevertheless, the
delayed-reactivation phenotype of some LAT- mutants sug-
gests that the role of the LAA is to enhance reactivation.
However, the protein is present during the latent phase of
infection. To explain these observations, we speculate that
the LAA may be inactive during the latent phase of infection
and may be activated by extracellular signals that trigger
reactivation. Alternatively, to be active the LAA may re-
quire a factor available only after reactivation is initiated.
Although both the function of the LAA and specific aspects
of its expression remain to be elucidated, the identification of
an LAT-encoded antigen in latently infected neurons may be
a step towards understanding the molecular mechanisms
involved in the control of HSV latency.
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